{"disease":{"id":"non-small-cell-lung-cancer-nsclc-with-high-pd-l1-expression-tumor-proportion-score-tps-50-as-monotherapy-pembrolizumab-in-combination-with-pemetrexed-and-platinum-pemetrexed-platinum-in-patients-with-a-pd-l1-tps-1-as-determined-by-an-fda-approved-test","name":"non small cell lung cancer nsclc with high pd l1 expression tumor proportion score tps 50 as monotherapy pembrolizumab in combination with pemetrexed and platinum pemetrexed platinum in patients with a pd l1 tps 1 as determined by an fda approved test"},"drugs":{"marketed":[{"drug_id":"pf-06823859","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50%) as monotherapy (pembrolizumab in combination with pemetrexed and platinum (pemetrexed + platinum) in patients with a PD-L1 TPS ≥ 1% as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}